Hydantoin Derivatives for Kv3 Channel Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for alternative modulators of Kv3.1 and Kv3.2 channels that demonstrate specific channel selectivity profiles and desirable pharmacokinetic parameters, particularly high brain availability, to effectively treat conditions such as hearing disorders, schizophrenia, and ataxia.
Innovation Solution
The development of compounds of formula (I), which include specific heterocyclic structures and functional groups, are designed to modulate Kv3.1 and Kv3.2 channels, offering potential therapeutic benefits for hearing disorders, schizophrenia, and ataxia, and can be administered in the form of pharmaceutical compositions or as prodrug derivatives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If known pharmacological agents (TEA, BDS toxins) are used to inhibit Kv3 channels, then channel inhibition is achieved, but selectivity and pharmacokinetic properties are insufficient
Solution Approach 1:
The patent employs systematic variation of chemical parameters in the hydantoin core structure, including substitution patterns at positions 3, 5, and 6 with diverse functional groups (halo, alkyl, alkoxy, aryl), to optimize both binding affinity for Kv3 channels and selectivity across different channel subtypes. This parameter optimization enables differentiation from non-selective agents like TEA
Solution Approach 2:
The Kv3 channel modulators are designed as distinct molecular entities with specific structural segments: a hydantoin core (N-C(=O)-N-C(=O)) divided into substitutable positions, allowing independent optimization of pharmacophoric elements for selectivity and pharmacokinetic properties
2Reliability
If compounds are designed for high brain availability, then therapeutic efficacy for CNS disorders is improved, but molecular complexity increases
Solution Approach 1:
The patent introduces specific lipophilic substituents (haloalkyl groups, aryl groups) at strategic positions on the hydantoin core to enhance blood-brain barrier penetration, while maintaining overall molecular simplicity through limited substitution patterns and avoiding excessive structural complexity
Solution Approach 2:
The compounds combine the hydantoin heterocyclic core with various substituent groups (halo, alkyl, alkoxy, aryl) to create composite molecular structures that integrate multiple pharmacological properties: channel binding affinity, brain penetration, and metabolic stability in a single molecule
Data Source
AI summary
The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.